GlassScriptPhysician profile
Randy J Yanda
NPI 1407850076
$4,998.60
in general payments reported to CMS, 2019-2025
33 companies · $614 in 2025
The $614 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $318 · 2021: $1,077 · 2022: $905 · 2023: $807 · 2024: $668 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.79 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,350.85 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $904.60 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $613.94 | 2019-2025 | Entyvio |
| Boston Scientific Corporation | $281.69 | 2020-2025 | General - Therapies, Orcapod, Exalt Model D |
| Janssen Biotech, INC. | $225.00 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $209.45 | 2021-2024 | Zeposia |
| Amgen INC. | $194.88 | 2021-2023 | Amjevita, Avsola |
| Pfizer INC. | $176.55 | 2019-2024 | |
| Genzyme Corporation | $155.13 | 2022-2025 | |
| Madrigal Pharmaceuticals | $142.49 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $102.23 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $83.55 | 2021-2024 | Dificid |
| Allergan, INC. | $79.99 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $57.20 | 2021-2023 | |
| Qol Medical, LLC | $40.23 | 2019-2025 | Sucraid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $34.92 | 2024-2025 | Vegzelma |
| Olympus America INC. | $32.63 | 2024 | Evis Exera III Colonovideoscope |
| Medtronic, INC. | $30.35 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $26.58 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $26.20 | 2021 | |
| Lilly USA, LLC | $25.92 | 2023 | |
| Biocon Biologics INC | $21.57 | 2025 | Yesintek |
| Sandoz INC. | $20.05 | 2023 | Hyrimoz |
| Ardelyx, INC. | $19.72 | 2025 | Ibsrela |
| Covidien LP | $19.69 | 2020 | |
| Vivus LLC | $17.68 | 2021 | |
| Daiichi Sankyo INC. | $17.61 | 2019 | |
| Braintree Laboratories, INC. | $17.32 | 2021 | |
| Ucb, INC. | $14.92 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.71 | 2019 | |
| Organon LLC | $14.54 | 2025 | Hadlima, Renflexis |
| Micro-Tech Endoscopy USA, INC. | $14.18 | 2021 | |
| Redhill Biopharma INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Yanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.